Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial
- 1 February 2002
- journal article
- Published by Elsevier in American Heart Journal
- Vol. 143 (2), 242-248
- https://doi.org/10.1067/mhj.2002.120145
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Disagreement between site investigators and clinical event committees is common and can affect trial resultsJournal of the American College of Cardiology, 1998
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable AnginaNew England Journal of Medicine, 1998
- Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial InfarctionNew England Journal of Medicine, 1998
- Myonecrosis After Revascularization ProceduresJournal of the American College of Cardiology, 1998
- A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary SyndromesNew England Journal of Medicine, 1996
- P73 Comparison of investigator and central events review of myocardial infarction rates as a means to improve events classification: Results from GUSTO-IIaControlled Clinical Trials, 1996
- A47 Differences in endpoint identification by investigators versus independent reviewControlled Clinical Trials, 1996
- Centralized systematic adjudication of clinical endpoints in multicenter trials of acute coronary syndromes identifies patients at high risk for adverse clinical outcomesJournal of the American College of Cardiology, 1996
- Surveillance and ascertainment of cardiovascular events: The Cardiovascular Health StudyAnnals of Epidemiology, 1995